Login / Signup

Real-life effectiveness and safety of baricitinib in patients with severe alopecia areata: A 24-week Italian study.

Bianca Maria PiracciniFrancesca PampaloniStephano CedirianF QuadrelliFrancesca BruniLuca RappariniGemma CaroM C AcriL AlaAlfredo RossiG PellacaniFrancesco LacarrubbaG MicaliF Dall'OglioMarina VastarellaM CantelliP NappaLaura DiluvioL BianchiLaura GnesottoAndrea SechiL NaldiF TassoneK PerisGiacomo CaldarolaL M PintoGiampiero GirolomoniF MarangoniFrancesco BellinatoPaolo GisondiI ScandagliFrancesca PrignanoN PimpinelliC TomasiniStefania BarruscottiEdoardo De SimoniO SimonettiF AmbrogioC FotiV BoccalettiA FraghìAngelo Valerio MarzanoM A MattioliL RoccaM BarbareschiS M FerrucciGiuseppe GalloSimone RiberoPietro QuaglinoR BalestriT IorisR D Caposiena CaroI ZalaudekE VagnozziMaria-Concetta FargnoliC CaponioP RubegniElisa CinottiEmanuele TrovatoM RomanelliValentina DiniFlavia Manzo MargiottaClaudio FelicianiM B de Felici Del GiudiceLaura AtzoriS SannaS LemboAnnunziata RaimondoMichela MagnanoMichela Valeria Rita Starace
Published in: Journal of the European Academy of Dermatology and Venereology : JEADV (2024)
Data on the effectiveness and safety of baricitinib are promising and support the use of this drug in severe forms of AA, also in the early stages. We also suggest performing trichoscopy in order to reveal early response to therapy.
Keyphrases
  • early onset
  • drug induced
  • electronic health record
  • emergency department
  • big data
  • randomized controlled trial
  • gene expression
  • machine learning
  • clinical trial
  • deep learning
  • smoking cessation